Vera Therapeutics (VERA) Insider Trading & Ownership $19.79 +0.07 (+0.35%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$19.80 +0.01 (+0.03%) As of 08/8/2025 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Vera Therapeutics (NASDAQ:VERA) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage16.30%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$5.28MNumber OfInsiders Selling(Last 12 Months)2Amount OfInsider Selling(Last 12 Months)$6.68M Get VERA Insider Trade Alerts Want to know when executives and insiders are buying or selling Vera Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address VERA Insider Buying and Selling by Quarter Vera Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails6/24/2025Patrick G EnrightDirectorBuy40,607$22.35$907,566.45 6/23/2025Patrick G EnrightDirectorBuy209,393$20.87$4,370,031.91 1/8/2025Marshall FordyceCEOSell17,500$41.74$730,450.00 12/18/2024Marshall FordyceCEOSell17,500$43.07$753,725.00 12/11/2024Marshall FordyceCEOSell17,500$46.94$821,450.00 10/28/2024Beth C SeidenbergDirectorSell15,000$48.03$720,450.00 10/23/2024Marshall FordyceCEOSell19,375$40.39$782,556.25 10/9/2024Marshall FordyceCEOSell15,625$38.24$597,500.00 9/25/2024Marshall FordyceCEOSell23,125$46.05$1,064,906.25 9/18/2024Beth C SeidenbergDirectorSell1,177$42.01$49,445.77 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 9/11/2024Marshall FordyceCEOSell15,625$37.50$585,937.50 8/21/2024Marshall FordyceCEOSell14,471$39.76$575,366.96 (Data available from 1/1/2013 forward) VERA Insider Trading Activity - Frequently Asked Questions Who is on Vera Therapeutics' Insider Roster? The list of insiders at Vera Therapeutics includes Beth C Seidenberg, Carlyle Group Inc., Celia Lin, Commodore Capital Lp, Joanne Curley, Joseph R Young, Maha Katabi, Marshall Fordyce, Patrick G Enright, Sean Grant, and Sofinnova Venture Partners X,. Learn more on insiders at VERA. What percentage of Vera Therapeutics stock is owned by insiders? 16.30% of Vera Therapeutics stock is owned by insiders. Learn more on VERA's insider holdings. Which Vera Therapeutics insiders have been buying company stock? The following insiders have purchased VERA shares in the last 24 months: Maha Katabi ($4,999,990.00), and Patrick G Enright ($5,277,598.36). How much insider buying is happening at Vera Therapeutics? Insiders have purchased a total of 411,290 VERA shares in the last 24 months for a total of $10,277,588.36 bought. Which Vera Therapeutics insiders have been selling company stock? The following insiders have sold VERA shares in the last 24 months: Beth C Seidenberg ($769,895.77), Celia Lin ($24,808.50), Commodore Capital Lp ($18,900,000.00), Joseph R Young ($228,560.00), Maha Katabi ($17,350,597.80), Marshall Fordyce ($5,998,690.56), and Sean Grant ($3,954,187.08). How much insider selling is happening at Vera Therapeutics? Insiders have sold a total of 1,740,149 Vera Therapeutics shares in the last 24 months for a total of $47,226,739.71 sold. Vera Therapeutics Key ExecutivesDr. Marshall W. Fordyce M.D. (Age 49)Founder, President, CEO & Director Compensation: $910.14kMr. Sean P. Grant M.B.A. (Age 39)Chief Financial Officer Compensation: $642kMr. Joseph R. Young M.B.A. (Age 51)Senior VP of Finance & Chief Accounting Officer Mr. Julien E. Capers J.D.VP & Head of LegalMs. Kelly RauberVP & Head of Human ResourcesMr. Tom Doan (Age 52)Senior Vice President of Development Operations Ms. Lauren Frenz (Age 39)Chief Business Officer Dr. Neeraj Pakala M.B.A.Ph.D., Senior VP and Head of Product Development & ManufacturingDr. Kerry Cooper M.D.Senior Vice President of Medical AffairsDr. Robert M. Brenner M.D. (Age 56)Chief Medical Officer More Insider Trading Tools from MarketBeat Related Companies CRISPR Therapeutics Insider Buying Lantheus Insider Buying ADMA Biologics Insider Buying Merus Insider Buying TG Therapeutics Insider Buying Avidity Biosciences Insider Buying Cytokinetics Insider Buying Vaxcyte Insider Buying Zai Lab Insider Buying PTC Therapeutics Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Strategy Insiders Buy In While Analysts Predict Big UpsideThe Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months This page (NASDAQ:VERA) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
